These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 26974271)

  • 1. A novel reduced intensity conditioning regimen for patients with high-risk hematological malignancies undergoing allogeneic stem cell transplantation.
    Hobbs GS; Kaur N; Hilden P; Ponce D; Cho C; Castro-Malaspina HR; Giralt S; Goldberg JD; Jakubowski AA; Papadopoulos EB; Sauter C; Koehne G; Yahalom J; Delvin S; Barker JN; Perales MA
    Bone Marrow Transplant; 2016 Jul; 51(7):1010-2. PubMed ID: 26974271
    [No Abstract]   [Full Text] [Related]  

  • 2. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Allogeneic stem cell transplantation for patients with advanced hematological malignancies: comparison of fludarabine-based reduced intensity conditioning versus myeloablative conditioning.
    Kim I; Lee KH; Choi Y; Keam B; Koo NH; Yoon SS; Yoo KY; Park S; Kim BK
    J Korean Med Sci; 2007 Apr; 22(2):227-34. PubMed ID: 17449929
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overview of Hematopoietic Cell Transplantation for the Treatment of Hematologic Malignancies.
    Singh N; Loren AW
    Clin Chest Med; 2017 Dec; 38(4):575-593. PubMed ID: 29128011
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stem-cell dose for allogeneic hematopoietic stem cell transplantation in hematological malignancies: is more better?
    Shimoni A; Nagler A
    Leuk Lymphoma; 2009 Sep; 50(9):1395-6. PubMed ID: 19672777
    [No Abstract]   [Full Text] [Related]  

  • 6. Lowered-intensity preparative regimen for allogeneic stem cell transplantation delays acute graft-versus-host disease but does not improve outcome for advanced hematologic malignancy.
    Levine JE; Uberti JP; Ayash L; Reynolds C; Ferrara JL; Silver SM; Braun T; Yanik G; Hutchinson R; Ratanatharathorn V
    Biol Blood Marrow Transplant; 2003 Mar; 9(3):189-97. PubMed ID: 12652470
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Allogeneic hematopoietic stem cell transplantation in elderly].
    Castagna L; Blaise D; Furst S
    Bull Cancer; 2011 Aug; 98(8):915-25. PubMed ID: 21835732
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduced intensity conditioning for allogeneic hematopoietic cell transplantation: current perspectives.
    Sandmaier BM; Mackinnon S; Childs RW
    Biol Blood Marrow Transplant; 2007 Jan; 13(1 Suppl 1):87-97. PubMed ID: 17222778
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Therapeutic effect of allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning regimens on hematological malignancies].
    Yuan X; Sun ZM; Liu HL; Geng LQ; Wang ZY; Tong J; Yao W
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Jun; 16(3):614-7. PubMed ID: 18549640
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel reduced intensity regimen for allogeneic hematopoietic stem cell transplantation associated with a reduced incidence of graft-versus-host disease.
    Miller KB; Roberts TF; Chan G; Schenkein DP; Lawrence D; Sprague K; Gorgun G; Relias V; Grodman H; Mahajan A; Foss FM
    Bone Marrow Transplant; 2004 May; 33(9):881-9. PubMed ID: 14990986
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparable kinetics of myeloablation between fludarabine/full-dose busulfan and fludarabine/melphalan conditioning regimens in allogeneic peripheral blood stem cell transplantation.
    Chunduri S; Dobogai LC; Peace D; Saunthararajah Y; Chen HY; Mahmud N; Quigley J; Hoffman R; Jessop E; Beri R; Rondelli D
    Bone Marrow Transplant; 2006 Oct; 38(7):477-82. PubMed ID: 16980995
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Non-myeloablative therapy and allogeneic hematopoietic stem cell transplantation in hematologic malignancies].
    Hansz J
    Pol Arch Med Wewn; 2001; 105 Suppl():173-5. PubMed ID: 12412244
    [No Abstract]   [Full Text] [Related]  

  • 13. Possibility of long-term remission in patients with advanced hematologic malignancies after reduced intensity conditioning regimen (RIC) and allogeneic stem cell transplantation.
    Picardi A; Fabritiis Pd Pd; Cudillo L; Dentamaro T; Cupelli L; Ballatore G; Venditti A; Caravita T; Cristina Cox M; Catalano G; Amadori S
    Hematol J; 2004; 5(1):24-31. PubMed ID: 14745426
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Successful allogeneic stem cell transplantation with nonmyeloablative conditioning in patients with relapsed hematologic malignancy following autologous stem cell transplantation.
    Dey BR; McAfee S; Sackstein R; Colby C; Saidman S; Weymouth D; Poliquin C; Vanderklish J; Sachs DH; Sykes M; Spitzer TR
    Biol Blood Marrow Transplant; 2001; 7(11):604-12. PubMed ID: 11760148
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conventional versus reduced-intensity conditioning regimen for allogeneic stem cell transplantation in patients with hematological malignancies.
    Valcárcel D; Martino R; Sureda A; Canals C; Altés A; Briones J; Sanz MA; Parody R; Constans M; Villela SL; Brunet S; Sierra J
    Eur J Haematol; 2005 Feb; 74(2):144-51. PubMed ID: 15654906
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictive factors for outcomes after reduced intensity conditioning hematopoietic stem cell transplantation for hematological malignancies: a 10-year retrospective analysis from the Société Française de Greffe de Moelle et de Thérapie Cellulaire.
    Michallet M; Le QH; Mohty M; Prébet T; Nicolini F; Boiron JM; Esperou H; Attal M; Milpied N; Lioure B; Bordigoni P; Yakoub-Agha I; Bourhis JH; Rio B; Deconinck E; Renaud M; Chir Z; Blaise D
    Exp Hematol; 2008 May; 36(5):535-44. PubMed ID: 18346838
    [TBL] [Abstract][Full Text] [Related]  

  • 17. GvHD prophylaxis with tacrolimus plus sirolimus after reduced intensity conditioning allogeneic transplantation: results of a multicenter study.
    Parody R; López-Corral L; Lopez-Godino O; Martinez C; Martino R; Solano C; Barba P; Caballero D; García-Cadenas I; Piñana JL; Marquez-Malaver FJ; Vazquez L; Esquirol A; Boluda JC; Sanchez-Guijo F; Pérez-Simon JA
    Bone Marrow Transplant; 2016 Nov; 51(11):1524-1526. PubMed ID: 27295268
    [No Abstract]   [Full Text] [Related]  

  • 18. Fludarabine vs cladribine plus busulfan and low-dose TBI as reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation: a prospective randomized trial.
    Markova M; Barker JN; Miller JS; Arora M; Wagner JE; Burns LJ; MacMillan ML; Douek D; DeFor T; Tan Y; Repka T; Blazar BR; Weisdorf DJ
    Bone Marrow Transplant; 2007 Feb; 39(4):193-9. PubMed ID: 17220905
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Review of Myeloablative vs Reduced Intensity/Non-Myeloablative Regimens in Allogeneic Hematopoietic Stem Cell Transplantations.
    Atilla E; Ataca Atilla P; Demirer T
    Balkan Med J; 2017 Jan; 34(1):1-9. PubMed ID: 28251017
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduced-intensity conditioning regimen using low-dose total body irradiation before allogeneic transplant for hematologic malignancies: Experience from the European Group for Blood and Marrow Transplantation.
    Belkacémi Y; Labopin M; Hennequin C; Hoffstetter S; Mungai R; Wygoda M; Lundell M; Finke J; Aktinson C; Lorchel F; Durdux C; Basara N
    Int J Radiat Oncol Biol Phys; 2007 Feb; 67(2):544-51. PubMed ID: 17141976
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.